General
Preferred name
ELVITEGRAVIR
Synonyms
Elvitegravir (GS-9137) ()
Genvoya-elvitegravir ()
GS-9137 ()
JTK-303 ()
D06677 ()
GS-9137,JTK-303,D06677 ()
Elvitegravir (JTK-303) ()
Vitekta ()
Elvitegravir component of genvoya ()
Elvitegravir component of stribild ()
Elvitegravir component of vitekta ()
Elvitegravir-d6 ()
P&D ID
PD009053
CAS
697761-98-1
Tags
available
drug
Approved by
EMA
PMDA
FDA
First approval
2012
Drug indication
Human immunodeficiency virus infection
HIV-1 infection
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Elvitegravir (GS-9137) is an HIV integrase inhibitor antiretroviral drug . (GtoPdb)
DESCRIPTION Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
Cell lines
1
Organisms
3
Compound Sets
19
AdooQ Bioactive Compound Library
A10347
Cayman Chemical Bioactives
17798
28523
ChEMBL Approved Drugs
CHEMBL204656
ChEMBL Drugs
CHEMBL204656
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB09101
DrugBank Approved Drugs
DB09101
DrugCentral
4300
DrugCentral Approved Drugs
4300
DrugMAP
DMG9B1U
DrugMAP Approved Drugs
DMG9B1U
EU-OPENSCREEN Bioactive Compound Library
EOS100650
Guide to Pharmacology
11574
MedChem Express Bioactive Compound Library
HY-14740
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
4GDQ854U53
ReFrame library
Selleckchem Bioactive Compound Library
Elvitegravir
External IDs
34
Properties
(calculated by RDKit )
Molecular Weight
447.12
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
3
Aromatic Ring Count
3
cLogP
4.28
TPSA
88.76
Fraction CSP3
0.3
Chiral centers
1.0
Largest ring
6.0
QED
0.56
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
human immunodeficiency virus (HIV-1)
MOA
HIV integrase inhibitor
Therapeutic Indication
Antiviral
Target
HIV
HIV Integrase
Integrase
Pathway
Anti-infection
Metabolic Enzyme/Protease
Source data